Clinical Trial

Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-10-23; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2025-12-09
Trial Details
NCT Number NCT07221344
Lead Sponsor Arrowhead Pharmaceuticals
Conditions Alzheimer Disease, Alzheimer Disease, Early Onset
Enrollment 112 participants
Start Date 2025-11-18
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-23